Our Partnerships

The future hinges on forging meaningful partnerships

 

 

We are passionate about advancing science and one of the futuristic ways is to partner with the brightest minds in science and healthcare. So that we can serve patients with difficult-to-treat diseases, both now and in future. Roche Pharma India has entered into promotion, marketing and distribution partnerships with Cipla and Entero with the aim to further improve access to trademark Oncology, Rheumatology/ Immunology, COVID-19 and Nephrology medicines.

Both our valued partnerships leverage the strong marketing and distribution strengths of our partners in India to provide broader access to our innovative and transformative treatments. Only through such symbiotic partnerships, we can hope to shape the future of healthcare in our country.


 

The partnership with Cipla includes promotion, marketing and distribution of our trademark Oncology and Rheumatology/ Immunology drugs as well as our antibody cocktail which is indicated for use in patients with mild to moderate COVID-19.

Brands in partnership with Cipla: Actemra (Tocilizumab) | Avastin (Bevacizumab) | Syndma (Bevacizumab) | Herclon (Trastuzumab) | Biceltis (Trastuzumab) | Ristova (Rituximab) | Ikgdar (Rituximab) | Ronapreve (Casirivimab & Imdevimab)

Brands with Cipla
Brands with Entero

 


 

As a part of this collaboration, Entero is responsible for promotion, marketing and distribution of Roche Pharma's Nephrology drugs for the Indian market.

Brands in partnership with Entero: Cellcept (Mycophenolate Mofetil) | Mircera (methoxy polyethylene glycol-epoetin beta) | Neorecormon (epoetin beta) | Valcyte (Valganciclovir)

 

 

 

Safety Update Information for Healthcare Professionals

I understand the following:

  1. The information contained in this Letter is for the sole purpose of use and knowledge of Healthcare Professionals (HCPs) Only. 
  2. If any Individual other than HCPs access the information contained in this Letter and act thereon, then Roche will not be liable for any consequences in relation thereto.
  3. Patients and their relatives should not access the information contained in this Letter. They are advised to consult their treating physicians.